Catalase application in cancer therapy: Simultaneous focusing on hypoxia attenuation and macrophage reprogramming.
Catalase
Hypoxia
Macrophage polarization
Nanozyme
Tumor microenvironment
Tumor-associated macrophage
Journal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
06
06
2022
revised:
26
07
2022
accepted:
26
07
2022
entrez:
9
9
2022
pubmed:
10
9
2022
medline:
14
9
2022
Statut:
ppublish
Résumé
The tumor microenvironment (TME), as an immunosuppressive milieu, has a critical role in tumor progression and increases resistance to the conventional treatments. Among the abundant immunosuppressive cells in the TME, tumor-associated macrophages (TAMs) could be a promising target for reprogramming and potentiating the local anti-tumor response. On the other hand, hypoxia is a major barrier in treating solid tumors, which aggravates the situation and alleviates the anti-tumor immune responses. Moreover, catalase and catalase-mimicking compounds can efficiently participate in the TAMs polarization and hypoxia attenuation in the TME. In this review, we will introduce a practical and novel approach which can simultaneously reduce hypoxia and polarize TAMs in the TME. Furthermore, catalase therapeutic effects in combination with cancer therapy methods will be fully discussed. This work aims to inspire readers to explore new avenues for designing and development of next-generation catalase-based formulations for cancer therapy.
Identifiants
pubmed: 36076502
pii: S0753-3322(22)00872-1
doi: 10.1016/j.biopha.2022.113483
pii:
doi:
Substances chimiques
Catalase
EC 1.11.1.6
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
113483Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest None to declare.